Isoprene in the exhaled breath is a novel biomarker for advanced fibrosis in patients with chronic liver disease: A pilot study

Clinical and Translational Gastroenterology

Volumn 6, Issue 9, 2015, Pages

  Alkhouri, Naim ^a   Singh, Tavankit ^a   Alsabbagh, Eyad ^a   Guirguis, John ^a   Chami, Tarek ^a   Hanouneh, Ibrahim ^a   Grove, David ^a   Lopez, Rocio ^a   Dweik, Raed ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 NONENE; 2 PROPANOL; 3 METHYLHEXANE; ACETALDEHYDE; ACETONE; ACRYLONITRILE; ALCOHOL; AMMONIA; BENZENE; CARBON DISULFIDE; CHOLESTEROL; DECENE; DIMETHYL SULFIDE; ETHANE; HEPTANE; HYDROGEN SULFIDE; ISOPRENE; NONENE; OCTANE; PENTANE; TRIETHYLAMINE; TRIMETHYLAMINE; UNCLASSIFIED DRUG; VOLATILE ORGANIC COMPOUND;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BREATH ANALYSIS; CHOLESTEROL SYNTHESIS; CHRONIC LIVER DISEASE; CONFIDENCE INTERVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EXPIRED AIR; FEMALE; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PATHOLOGIST; PILOT STUDY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; YOUNG ADULT;

EID: 84989360830     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2015.40     Document Type: Article

References (21)

1. Younossi ZM, Stepanova M, Afendy M et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530.
2. Volk ML, Tocco RS, Bazick J et al. Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol 2012; 107: 247-252.
3. Minino AM, Murphy SL, Xu J et al. Deaths: final data for 2008. Natl Vital Stat Rep 2011; 59: 1-126.
4. Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol 2014; 20: 16820-16830.
5. Rockey DC, Caldwell SH, Goodman ZD et al. Liver biopsy. Hepatology 2009; 49: 1017-1044.
6. Scott R, Guha IN. Non-invasive monitoring of liver fibrosis. Br Med Bull 2014; 112: 97-106.
7. Hepner GW, Vesell ES. Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis. N Engl J Med 1974; 291: 1384-1388.
8. Giannini EG, Fasoli A, Borro P et al. 13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease. Clin Gastroenterol Hepatol 2005; 3: 279-285.
9. Portincasa P, Grattagliano I, Lauterburg BH et al. Liver breath tests non-invasively predict higher stages of non-alcoholic steatohepatitis. Clin Sci (Lond) 2006; 111: 135-143.
10. Park GJ, Wiseman E, George J et al. Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test. J Gastroenterol Hepatol 2011; 26: 1411-1416.
11. Giannini E, Fasoli A, Chiarbonello B et al. 13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2002; 16: 717-725.
12. Hanouneh IA, Zein NN, Cikach F et al. The breathprints in patients with liver disease identify novel breath biomarkers in alcoholic hepatitis. Clin Gastroenterol Hepatol 2014; 12: 516-523.
13. Alkhouri N, Cikach F, Eng K et al. Analysis of breath volatile organic compounds as a noninvasive tool to diagnose nonalcoholic fatty liver disease in children. Eur J Gastroenterol Hepatol 2014; 26: 82-87.
14. Mashir A, Paschke KM, van Duin D et al. Effect of the influenza A (H1N1) live attenuated intranasal vaccine on nitric oxide (FE(NO)) and other volatiles in exhaled breath. J Breath Res 2011; 5: 037107.
15. Prince BJ, Milligan DB, McEwan MJ. Application of selected ion flow tube mass spectrometry to real-time atmospheric monitoring. Rapid Commun Mass Spectrom 2010; 24: 1763-1769.
16. Smith D, Spanel P. Selected ion flow tube mass spectrometry (SIFT-MS) for on-line trace gas analysis. Mass Spectrom Rev 2005; 24: 661-700.
17. Langford VS, Graves I, McEwan MJ. Rapid monitoring of volatile organic compounds: a comparison between gas chromatography/mass spectrometry and selected ion flow tube mass spectrometry. Rapid Commun Mass Spectrom 2014; 28 p 10-18.
18. Dadamio J, Van den Velde S, Laleman W et al. Breath biomarkers of liver cirrhosis. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 905: 17-22.
19. Van den Velde S, Nevens F, Van Hee P et al. GC-MS analysis of breath odor compounds in liver patients. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 875: 344-348.
20. Stone BG, Besse TJ, Duane WC et al. Effect of regulating cholesterol biosynthesis on breath isoprene excretion in men. Lipids 1993; 28: 705-708.
21. Deneris ES, Stein RA, Mead JF. In vitro biosynthesis of isoprene from mevalonate utilizing a rat liver cytosolic fraction. Biochem Biophys Res Commun 1984; 123: 691-696.